Soluble Fas (APO‐1, CD95) and soluble Fas ligand in rheumatic diseases

Derivation of the sledai. A disease activity index for lupus patients

1992 • 4,410 citations

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

1992 • 2,932 citations

Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family

1993 • 2,546 citations

Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation

1995 • 1,549 citations

Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule

1994 • 1,120 citations

Metalloproteinase-mediated release of human Fas ligand.

1995 • 835 citations

Fas ligand in human serum

1996 • 682 citations

Expression of the Fas ligand in cells of T cell lineage.

1995 • 659 citations

Expression of the functional soluble form of human fas ligand in activated lymphocytes.

1995 • 656 citations

Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase.

1994 • 582 citations

Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus.

1994 • 555 citations

Levels of soluble fas/APO‐1 /CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis

1995 • 84 citations

Lack of correlation between serum soluble fas/APO‐1 levels and autoimmune disease

1995 • 63 citations

Rheumatoid arthritis treated with tenidap and piroxicam clinical associations with cytokine modulation by tenidap

1995 • 26 citations